OPKO Health, Inc. (NASDAQ: OPK) had its price target lowered by analysts at LADENBURG THALM/SH SH from $5.75 to $5.40.
Opko Health, Inc. (OPK)
Last opko health, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.opko.com
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
OPK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPK alerts
High impacting Opko Health, Inc. news events
Weekly update
A roundup of the hottest topics
OPK
News
- OPKO Health, Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.MarketBeat
- OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic DisordersGlobeNewswire
- GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis [Yahoo! Finance]Yahoo! Finance
- GeneDx to Showcase Key Research and Innovation at the 2025 American College of Medical Genetics (ACMG) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- OPKO Health, Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.MarketBeat
OPK
Earnings
- 2/27/25 - Beat
OPK
Sec Filings
- 3/21/25 - Form 10-K/A
- 3/17/25 - Form 4
- 3/14/25 - Form ARS
- OPK's page on the SEC website